Jordan Ciuro, MD
Hematology & Oncology · Augusta, GANPI 1851741789
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,176 of the $7,646 with a category attached, or 67.7%. Johnson & Johnson accounts for 86.8% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $6,703, more than ten times the $260 reported in 2019.
Across 24 payments — averaging $318.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- E.r. Squibb & Sons, L.L.C.$230
- AstraZeneca$190
- Gilead$120
- Genentech USA, Inc.$109
- Seagen Inc.$102
- plus $259 from 4 others
Across 1 payment — averaging $1683.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Consulting fees$5,17668%
- Travel & lodging$1,41919%
- Food & beverage$79510%
- Education$2553%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $6,635 |
| E.r. Squibb & Sons, L.L.C. | 4 | $230 |
| AstraZeneca(2 entities) | 2 | $190 |
| Gilead | 1 | $120 |
| Genentech USA, Inc. | 1 | $109 |
| Seagen Inc. | 1 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| AVEO Pharmaceuticals, Inc. | 1 | $87 |
| ADC Therapeutics America, Inc. | 1 | $59 |
| Apellis Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,646 in reported general payments places this provider in the 60th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 50 | $628,778 |
| Abiraterone Acetate | 61 | $192,163 |
| VerzenioAbemaciclib | 11 | $165,757 |
| InlytaAxitinib | 12 | $115,878 |
| OrgovyxRelugolix | 17 | $41,532 |
| Tamoxifen Citrate | 44 | $558 |
| Anastrozole | 43 | $557 |
| Prochlorperazine Maleate | 27 | $396 |
| Oxycodone Hcl | 22 | $348 |
| Prednisone | 71 | $204 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $91 |
| Amlodipine Besylate | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Augusta
- Jigarkumar ParikhAugusta$267K
- Abdullah KutlarAugusta$196K
- Vamsi KotaAugusta$91K
- Girindra RavalAugusta$88K
- Brent LimbaughAugusta$72K
- Amany KeruakousAugusta$36K
- Eugene LongAugusta$34K
- David SquiresAugusta$33K
- Miriam AtkinsAugusta$28K
- Priya RudolphAthens$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.